Robert Pilarski
Overview
Explore the profile of Robert Pilarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrison L, Bergeron G, Cadieux G, Charest H, Fafard J, Levade I, et al.
Ann Intern Med
. 2022 Dec;
176(1):67-76.
PMID: 36508736
Background: Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. Objective: To characterize the outbreak of monkeypox in Montréal, the first large outbreak in North...
2.
Knox D, Pilarski R, Dhunna H, Kaushal A, Adachi J
Can J Infect Dis Med Microbiol
. 2022 Sep;
2022:3913439.
PMID: 36081603
According to the Public Health Agency of Canada, approximately 62,050 people were living with HIV in Canada in 2018, and of those, 13% were undiagnosed. Currently, no single strategy provides...
3.
Horton C, Cass A, Conner B, Hoang L, Zimmermann H, Abualkheir N, et al.
NPJ Genom Med
. 2022 Aug;
7(1):49.
PMID: 36008414
DNA germline genetic testing can identify individuals with cancer susceptibility. However, DNA sequencing alone is limited in its detection and classification of mRNA splicing variants, particularly those located far from...
4.
Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626031
Consensus guidelines for hereditary breast and ovarian cancer include management recommendations for pathogenic/likely pathogenic (P/LP) variants in , , and other DNA damage repair (DDR) genes beyond or . We...
5.
Black M, Li S, Pesaran T, LaDuca H, Karam R, Clifford J, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-7.
PMID: 35172517
Purpose: mutations are associated with breast, colon, endometrial, kidney, and thyroid cancers. Most promoter alterations, however, are characterized as variants of unknown significance, and their contribution to cancer risk is...
6.
Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, et al.
Breast Cancer Res Treat
. 2021 Jan;
186(2):569-575.
PMID: 33507482
Background: Concurrent germline (g) pathogenic variants related to hereditary breast cancer represent a rare occurrence. While double heterozygosity in gBRCA1 and gBRCA2 has been reported in the past, herein we...
7.
Drelles K, Pilarski R, Manickam K, Shoben A, Toland A
Public Health Genomics
. 2021 Jan;
24(1-2):26-32.
PMID: 33445171
Introduction: Pharmacogenetic (PGx) testing can be useful for providing information about a patient's drug response by increasing drug efficacy and decreasing the incidence of adverse drug events. While PGx tests...
8.
Anderson J, Pilarski R, Kirschner L, Brock P
Fam Cancer
. 2021 Jan;
21(1):93-100.
PMID: 33409929
Hereditary endocrine tumor syndromes are rare conditions with overlapping features. It is imperative that healthcare providers differentiate between these syndromes for proper patient care. Advances in genetic testing technologies have...
9.
Pilarski R
J Natl Compr Canc Netw
. 2021 Jan;
19(1):103-108.
PMID: 33406496
Historically, genetic testing (and billing) for hereditary cancer risk was essentially performed gene by gene, with clinicians ordering testing only for the genes most likely to explain a patient's or...
10.
Giri V, Knudsen K, Kelly W, Cheng H, Cooney K, Cookson M, et al.
J Clin Oncol
. 2020 Jun;
38(24):2798-2811.
PMID: 32516092
Purpose: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data,...